Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease

被引:25
|
作者
Zhou, Cheng [1 ]
Wang, Linbo [2 ,3 ,4 ,5 ]
Cheng, Wei [2 ,3 ,4 ,5 ,6 ]
Lv, JinChao [2 ]
Guan, Xiaoujun [1 ]
Guo, Tao [1 ]
Wu, Jingjing [1 ]
Zhang, Wei [2 ,3 ,4 ,5 ]
Gao, Ting [7 ]
Liu, Xiaocao [1 ]
Bai, Xueqin [1 ]
Wu, Haoting [1 ]
Cao, Zhengye [1 ]
Gu, Luyan [7 ]
Chen, Jingwen [1 ]
Wen, Jiaqi [1 ]
Huang, Peiyu [1 ]
Xu, Xiaojun [1 ]
Zhang, Baorong [7 ]
Feng, Jianfeng [2 ,3 ,4 ,5 ,6 ]
Zhang, Minming [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Radiol, Hangzhou 310000, Peoples R China
[2] Fudan Univ, Inst Sci & Technol Brain Inspired Intelligence, Shanghai 200433, Peoples R China
[3] Fudan Univ, Key Lab Computat Neurosci & Brain Inspired Intelli, Minist Educ, Shanghai, Peoples R China
[4] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China
[5] Zhangjiang Fudan Int Innovat Ctr, Shanghai, Peoples R China
[6] Univ Warwick, Dept Comp Sci, Coventry CV4 7AL, England
[7] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310000, Peoples R China
基金
中国国家自然科学基金;
关键词
PROGRESSION MARKER; BIOMARKERS; PATHOLOGY; PATTERNS; SUBTYPES; ATROPHY;
D O I
10.1038/s41531-023-00556-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence suggests that Parkinson's disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique-Subtype and Stage Inference (SuStaIn) - to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Parkinson's Disease 2 The pathogenesis of Parkinson's disease
    Morris, Huw R.
    Spillantini, Maria Grazia
    Sue, Carolyn M.
    Williams-Gray, Caroline H.
    LANCET, 2024, 403 (10423) : 293 - 304
  • [42] Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
    Murray, Melissa E.
    Graff-Radford, Neill R.
    Ross, Owen A.
    Petersen, Ronald C.
    Duara, Ranjan
    Dickson, Dennis W.
    LANCET NEUROLOGY, 2011, 10 (09) : 785 - 796
  • [43] Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates
    van den Berg, Kevin R. E.
    Johansson, Martin E.
    Dirkx, Michiel F.
    Bloem, Bastiaan R.
    Helmich, Rick C.
    MOVEMENT DISORDERS, 2025, 40 (02) : 292 - 304
  • [44] Neurodegeneration in Parkinson disease Moving Lewy bodies out of focus
    Schulz-Schaeffer, Walter J.
    NEUROLOGY, 2012, 79 (24) : 2298 - 2299
  • [45] Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis
    Liu, Ping
    Feng, Tao
    Wang, Yong-jun
    Zhang, Xuan
    Chen, Biao
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2011, 12 (09): : 694 - 703
  • [46] Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease
    Mattsson, Niklas
    Schott, Jonathan M.
    Hardy, John
    Turner, Martin R.
    Zetterberg, Henrik
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (09) : 1000 - 1004
  • [47] Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
    Wang, Hui-Fu
    Shen, Xue-Ning
    Li, Jie-Qiong
    Suckling, John
    Tan, Chen-Chen
    Wang, Yan-Jiang
    Feng, Lei
    Zhang, Can
    Tan, Lan
    Dong, Qiang
    Touchon, Jacques
    Gauthier, Serge
    Yu, Jin-Tai
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [48] Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment
    Simon-Gozalbo, Ana
    Rodriguez-Blazquez, Carmen
    Forjaz, Maria J.
    Martinez-Martin, Pablo
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [49] Clinical Markers for Identifying Cholinergic Deficits in Parkinson's Disease
    Mueller, Martijn L. T. M.
    Bohnen, Nicolaas I.
    Kotagal, Vikas
    Scott, Peter J. H.
    Koeppe, Robert A.
    Frey, Kirk A.
    Albin, Roger L.
    MOVEMENT DISORDERS, 2015, 30 (02) : 269 - 273
  • [50] Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease
    Frank, Anika
    Bendig, Jonas
    Schnalke, Nils
    Klingelhoefer, Lisa
    Reichmann, Heinz
    Akguen, Katja
    Ziemssen, Tjalf
    Falkenburger, Bjoern H.
    NPJ PARKINSONS DISEASE, 2024, 10 (01)